Wexford Capital LP Silence Therapeutics PLC Transaction History
Wexford Capital LP
- $638 Million
- Q3 2025
A detailed history of Wexford Capital LP transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Wexford Capital LP holds 7,708 shares of SLN stock, worth $52,953. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,708
Previous 27,149
71.61%
Holding current value
$52,953
Previous $157,000
74.52%
% of portfolio
0.01%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding SLN
# of Institutions
54Shares Held
20.6MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$20.8 Million1.76% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$20 Million0.59% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$14.9 Million1.24% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.84MShares$12.7 Million0.69% of portfolio
-
Morgan Stanley New York, NY1.21MShares$8.3 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $247M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...